Amarin Announces Submission of Supplemental New Drug Application for Novasep as Fourth Vascepa(R) Active Pharmaceutical Ingredient Supplier Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Submission of Supplemental New Drug Application for Novasep as Fourth Vascepa(R) Active Pharmaceutical Ingredient Supplier
Amarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia
Amarin Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Update on Operations Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Update on Operations
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa(R) and Planned ANCHOR Indication Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa(R) and Planned ANCHOR Indication
Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R) Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R)
Amarin Announces Approval of Supplemental New Drug Application for Chemport as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Approval of Supplemental New Drug Application for Chemport as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and
Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013 Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013
Amarin Reports First Quarter 2013 Financial Results and Provides Update on Operations Submitted by amarin on Fri, 12/08/2017 - 04:49 Home Read more about Amarin Reports First Quarter 2013 Financial Results and Provides Update on Operations
